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MEETING PROCEEDINGSHighlights from Transcatheter Cardiovascular Therapeutics 2009:
San Francisco, California, September 21 to 25, 2009Jeffrey M. Sparling, MD, and Frederic S. Resnic, MD, MSc, FACCTranscatheter Cardiovascular Therapeutics, the annual
interventional cardiology scientific symposium, was held
September 21 to 25, 2009, in San Francisco, California.
This internationally attended meeting was the venue for
the release of new clinical trial data and an ongoing compre-
hensive review of many subjects of interest to the cardiotho-
racic surgical community.OUTCOMES IN 3-VESSEL CORONARYARTERY
DISEASE AND LEFT MAIN CORONARYARTERY
DISEASE AFTER REVASCULARIZATION
The SYNTAX investigators presented an ongoing analy-
sis examining outcomes in patients requiring repeat revascu-
larization after initial coronary artery bypass grafting
(CABG) or multivessel or left main (LM) percutaneous cor-
onary intervention (PCI). Of the 1800 patients initially en-
rolled, 224 required a repeat procedure, primarily in the
first 6 months after the index revascularization. The primary
need for a second procedure was recurrent angina, regardless
of arm of enrollment. Patients undergoing CABG as the ini-
tial procedure required less repeat revascularization than
those receiving multivessel stents (8.6% vs 17.4%,
P< .001). Predictors of the need for a repeat revasculariza-
tion included medically treated diabetes mellitus in the PCI
group and initial treatment for unstable angina or urgent re-
vascularization in the CABG arm. Regardless of the type of
initial treatment arm, ‘‘complete’’ revascularization at the
time of index procedure reduced the need for a subsequent
repeat revascularization.1
Investigators continue to examine the SYNTAX score as
a means of predicting outcomes after percutaneous interven-
tion in traditionally high-risk anatomy. PCI of unprotected
(LM) coronary artery lesions seems to be as efficacious as
CABG at 15 months for isolated LM disease when the SYN-
TAX score is acceptably low (indicating freedom from addi-
tional complex coronary artery disease). Dr Marie-Claude
Morice presented data regarding contemporary indications
for LM revascularization techniques in the trial. This was in-
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istics and symptoms of restenosis in large epicardial vessels,
such as the LM coronary artery in the SYNTAX trial. The
15-month angiographic evaluation of this subset of patients
revealed that 92% of LM drug-eluting stents were still
widely patent (particularly in those patients with a low SYN-
TAX score) and that 26% of patients who underwent CABG
had at least 1 graft totally occluded, although graft occlusion
had no clinical consequence in terms of major adverse clin-
ical events.2
A 4-year review examining the predictive value of the
SYNTAX score in LM PCI outcomes studied consecutive
patients undergoing CABG or PCI for isolated LM disease
or LM disease with associated 1-vessel coronary artery dis-
ease. Results were similar to those reported in SYNTAX, re-
flecting that mortality trends in PCI directly correlated with
SYNTAX score. An increased score directly correlated with
increased mortality in patients undergoing LM PCI
compared with CABG, whereas outcomes after PCI in
patients with low scores were similar to those after surgical
revascularization.3
A similar study from Italy comparing 5-year outcomes in
unprotected LM PCI with CABG examined major adverse
cardiac and cerebrovascular events in consecutive patients
undergoing PCI or CABG. Investigators performed a pro-
pensity analysis examining outcomes 5 years after revascu-
larization, illustrating that major adverse cardiac and
cerebrovascular events were improved in the PCI cohort
(11.2% vs 20.4%, P¼ .004), whereas the rate of target ves-
sel revascularization procedures was lower in the CABG
group (28% vs 8.4%, P ¼ .0004).4
The accumulating evidence presented at Transcatheter
Cardiovascular Therapeutics indicates that anatomic com-
plexity, rather than LM coronary artery location by itself,
predicts major clinical events after PCI, although longer-
term follow-up of all studies is required.
PHARMACOLOGY OFACUTE CORONARY
SYNDROMES AND CORONARYARTERY DISEASE
Multiple presentations were made on various pharmaco-
logic agents used in the treatment of acute coronary syn-
drome (ACS), many of which have direct implications on
the patient who has already undergone cardiac surgery or
for whom CABG may be contemplated.
Deepak Bhatt, MD, presented the initial results of the
COGENT trial, the first randomized clinical data regarding
the interactions between clopidogrel and the proton pump
inhibitor omeprazole. Previous observational studies,rdiovascular Surgery c Volume 139, Number 2 515
Meeting Proceedings Sparling and Resnicincluding a large cohort of more than 8200 patients exam-
ined in a retrospective manner over a 3-year period, had sug-
gested a possible negative interaction between the 2 classes
of medication resulting in reduced efficacy of platelet inhibi-
tion, a clinically important scenario because many patients
with cardiovascular disease who are receiving dual-antipla-
telet therapy are receiving concomitant proton pump inhibi-
tor therapy.5 The results strongly demonstrated a lack of
interaction between the 2 medications as demonstrated by
equivalent survival and rates of major adverse cardiac
events, suggesting no reduction in clinical efficacy of clopi-
dogrel in patients receiving omeprazole. Gastrointestinal
end points were significantly increased in the group receiv-
ing clopidogrel and placebo compared with those receiving
clopidogrel and omeprazole.6
Shamir Mehta, MD, presented results of the CURRENT-
STEMI PCI study on behalf of the CURRENT investigators.
This study was designed to examine the effects of double-
dose clopidogrel (600 mg load, 150 mg daily for 6 days,
then 75 mg daily ongoing) compared with standard clopi-
dogrel dosing (300 mg load, then 75 mg ongoing) in patients
undergoing primary PCI for ST-elevation myocardial infarc-
tion (STEMI). This strategy had already been validated in
CURRENT-OASIS 7 as significantly reducing ischemic
events and stent thrombosis rates in patients with ACS
who are undergoing percutaneous intervention.7 Of the
6346 patients with STEMI who were enrolled, the double-
dose clopidogrel strategy significantly reduced ischemic
events, including a 46% relative risk reduction in stent
thrombosis, without increasing the risk of bleeding.8
The PLATelet inhibition and patient Outcomes trial
sought to compare the novel oral, reversible P2Y12 platelet
antagonist ticagrelor with clopidogrel in patients undergoing
PCI for ACS or STEMI. Ticagrelor is unique because it is
not a pro-drug (as clopidogrel is) and does not require met-
abolic activation, resulting in more rapid onset of platelet in-
hibition. Also, because it is reversibly bound it has a faster
offset of action resulting in functional recovery of circulat-
ing platelets in approximately 48 hours, which has important
implications for patients potentially needing both cardiac
and noncardiac surgery while receiving dual-antiplatelet
therapy. Chris Cannon, MD, on behalf of the PLATelet in-
hibition and patient Outcomes investigators, reported that
in patients undergoing PCI, ticagrelor effectively reduced
cardiovascular death, myocardial infarction, or stroke com-
pared with clopidogrel (9.02% vs 10.65%, P ¼ .0025),
without evidence of increased risk of bleeding.9
SURGICAL TECHNIQUES AND OUTCOMES
Additional pertinent topics during the week-long confer-
ence included reviews of cardiac and vascular surgery in
elderly patients and diabetic patients; both advocated careful
patient selection and evaluation when determining the
optimal method of revascularization in these subgroups. In516 The Journal of Thoracic and Cardiovascular Surgdiabetic patients, patient profiling using operative risk scores
such as EUROSCORE and SYNTAX can be useful tools to
orient the clinician as to the optimal revascularization strat-
egy, because diabetic patients with low-risk profiles can be
adequately and effectively revascularized by both percutane-
ous and surgical means.10,11
Hybrid interventional and surgical coronary revasculari-
zation was the topic of significant discussion during the
Transcatheter Cardiovascular Therapeutics meeting. The
cost-effectiveness of hybrid revascularization was explored
and reported demonstrative advantage for hybrid revascular-
ization, particularly in the setting of high-risk patients with
high SYNTAX scores.12 Many questions remain about the
proper sequencing of a hybrid procedure (surgery first,
PCI first, or simultaneous procedure), particularly as it re-
lates to antithrombotic and antiplatelet strategies, and multi-
ple presentations were made addressing this issue. Robert
Poston, MD, presented single-center consecutive patient ob-
servational data of 55 patients undergoing hybrid CABG
demonstrating that regardless of the order of the procedure,
hybrid bypass/PCI was safe and effective. There was no dif-
ference in bleeding outcomes regardless of the sequence as
measured by chest tube output and TIMI major bleeding
score, even in the simultaneous procedures or the PCI-first
procedures, for which all patients received preprocedural
clopidogrel loading doses.13
Roxana Mehran, MD, presented a review on left internal
thoracic artery (LITA) angiography after CABG. She re-
viewed early angiographic patency rates of LITA grafting
postsurgically, including both traditional CABG and mini-
mally invasive direct CABG. Review of data confirmed
that the LITA remains an excellent conduit for bypass,
with patency rates of approximately 95%. She cautioned
that clinical and angiographic variables should be carefully
considered before the decision is made to intervene percuta-
neously on a LITA graft, especially in the early postopera-
tive period, because the angiographic appearance of
a LITA graft (especially at the anastomotic site) may vary
depending on the healing process and flow characteristics.14
Advanced surgical techniques were presented in a main
session on Wednesday, September 23. Michael Argenziano,
MD, discussed minimally invasive mitral valve surgery, in-
cluding attempts to improve on the highly efficacious gold
standard open valvular repair by improving the morbidity
associated with the procedure (recovery time, wound com-
plications, bleeding, and cosmesis) via the use of minimally
invasive techniques. He presented the Columbia Hospital
experience, including a propensity analysis of 1005 isolated
mitral valvular repair cases performed via the standard or
minimally invasive approach with 4-year follow up. Al-
though aortic crossclamp time and cardiopulmonary bypass
times were slightly increased in the minimally invasive
group, length of stay and 30-day and 1-year mortality
were decreased.15ery c February 2010
Sparling and Resnic Meeting ProceedingsAdvances in surgically implanted ventricular assist de-
vices were also presented, particularly focusing on the de-
velopment and availability of future technologies. Robert
Dowling, MD, discussed extensively current and future gen-
erations of left ventricular assist devices, including continu-
ous-flow, chronic counterpulsation, and centrifugal pump
devices that are either currently involved in or have just com-
pleted clinical trial assessment. Technology in this field
continues to evolve toward smaller devices requiring less-
invasive surgical techniques for placement and reduction
in the neurologic complications associated with placement
and the need for associated anticoagulation. These develop-
ments all indicate a potential candidacy for ventricular assist
device insertion in patients classically considered too
‘‘well’’ to undergo placement of a mechanical support de-
vice, which is precisely the patient population currently be-
ing randomized in the Randomized Evaluation of VAD
InterVEntion before Inotropic Therapy trial, which Dr Dow-
ling discussed. This National Institutes of Health-funded
trial examines survival and quality of life indicators in pa-
tients with a ventricular assist device implanted who, before
implant, were neither inotrope-dependent nor exercise-intol-
erant and who had no evidence of end-organ involvement.16
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